Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ConsumerLab saw palmetto

This article was originally published in The Tan Sheet

Executive Summary

Seventeen of 22 saw palmetto supplements evaluated contain ingredients "similar to those known to work in clinical studies," online testing firm announces May 20. Two failing products were found to contain roughly half the amount of saw palmetto known to work, ConsumerLab.com notes, while one supplement contained "unusually high levels of sterols and specific fatty acids, suggesting the addition of undeclared oil in the product." NBTY, NOW Foods among firms with "passing" supplements. Review is second on saw palmetto supplements to be conducted by ConsumerLab; last test in 2000 passed eight of 13 products (1"The Tan Sheet" August 20, 2000, p. 6)...

You may also be interested in...



CR Saw Palmetto Review Produces Mixed Results; More Tests Upcoming

Only eight of 13 saw palmetto supplements tested by Consumer Reports contain an adequate amount of the extract, the magazine reports in its September issue.

California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation

CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.

CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales

Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095493

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel